ClinicalTrials.gg
TerminatedNCT03843125SLE-BRAVE-XUpdated May 16, 2023Results posted

A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE)

A Phase 3 interventional study of Baricitinib and Placebo in Systemic Lupus Erythematosus, sponsored by Eli Lilly and Company. Terminated at 297 sites in 32 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-05-16.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Why this study was terminated
Study terminated due to insufficient evidence to support a positive benefit: risk profile. Safety findings were consistent with previously published OLUMIANT data

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,147
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Lupus Erythematosus, Systemic by Eli Lilly and Company — 1 open to participants now, 1 under way, none of them phase 3. Lupus Erythematosus, Systemic · Eli Lilly and Company.

Enrollment
3rd of 11
1,147 · median 778
Started
2019
with 1 other
Phase 3
7 of 11
none open now
Registered
8th of 11
by date

Among the 11 studies in Lupus Erythematosus, Systemic by Eli Lilly and Company, this one is the 3rd largest by enrollment, is one of 2 that started in 2019, is one of 7 in phase 3, and was the 8th registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

1 of the 11 studies in Lupus Erythematosus, Systemic by Eli Lilly and Company is open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Lupus Erythematosus, Systemic by Eli Lilly and Company, or all of them as a file.
02

Study summary

The reason for this long term study is to see how safe and effective the study drug known as baricitinib is in participants with systemic lupus erythematosus (SLE) who have completed the final treatment visit of study I4V-MC-JAHZ (NCT03616912) or study I4V-MC-JAIA (NCT03616964).

03

Conditions studied

  • Systemic Lupus Erythematosus

Keywords

  • SLE
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Have completed the final treatment study visit of an originating study, such as study JAHZ (NCT03616912) or Study JAIA (NCT03616964).
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,147 participants (actual)

Study arms

  • Experimental
    2 mg Baricitinib

    Participants received one 2 mg Baricitinib tablet and one placebo tablet matching 4 mg Baricitinib administered orally every day (QD).

    Drug: Baricitinib · Drug: Placebo

  • Experimental
    4 mg Baricitinib

    Participants received one 4 mg Baricitinib tablet and one placebo tablet matching 2 mg Baricitinib administered orally QD.

    Drug: Baricitinib · Drug: Placebo

  • Experimental
    Placebo to 2 mg Baricitinib

    Participants who received placebo in the originating study (JAHZ or JAIA) were randomized to receive 2 mg Baricitinib administered orally QD.

    Drug: Baricitinib · Drug: Placebo

  • Experimental
    Placebo to 4 mg Baricitinib

    Participants who received placebo in the originating study (JAHZ or JAIA) were randomized to receive 4 mg Baricitinib administered orally QD.

    Drug: Baricitinib · Drug: Placebo

Interventions

  • Administered orally.

    Also known as: LY3009104

  • DrugPlacebo

    Administered orally.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)

    Percentage of participants with TEAEs. A treatment-emergent AE (TEAE) is defined as an event that first occurred or worsened in severity after the first dose of study treatment in Study JAIM and on or prior to the last visit date during the analysis period. The analysis period is defined as the treatment period plus up to 30 days off-drug follow-up time. A summary of serious and other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events module.

    Time frame: Week 134

  2. Percentage of Participants With Adverse Events of Special Interest (AESIs)

    Percentage of Participants with AESIs. AESI consisted of infections, positively adjudicated arterial thromboembolic events (ATE), positively adjudicated venous thromboembolic events (VTE), positively adjudicated major adverse cardiovascular events (MACE), other positively adjudicated cardiovascular events, death, anaphylactic reactions, hypersensitivity, angioedema, and malignancies.

    Time frame: Week 134

  3. Percentage of Participants With Serious Adverse Events (SAEs)

    Percentage of participants with SAEs. An SAE is any AE from this study that results in one of the following outcomes: Death; Initial or prolonged inpatient hospitalization; A life-threatening experience (that is, immediate risk of dying); Persistent or significant disability/incapacity; Congenital anomaly/birth defect; Important medical events that may not be immediately life-threatening or result in death or hospitalization, but may jeopardize the patient or may require intervention to prevent one of the other outcomes listed in the definition above. A summary of all SAE's, regardless of causality, is located in the Reported Adverse Events section.

    Time frame: Week 134

  4. Percentage of Participants With Temporary Investigational Product Interruptions

    Percentage of participants with temporary investigational product interruptions.

    Time frame: Week 134

  5. Percentage of Participants With Permanent Investigational Product Discontinuations

    Percentage of participants with permanent investigational product discontinuations.

    Time frame: Week 134

Secondary outcomes

  1. Percentage of Participants Achieving a Systemic Lupus Erythematosus Responder Index 4 (SRI-4) Response

    SRI-4 response defined as 1)greater than or equal to 4-point reduction in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) total score 2)no new British Isles Lupus Assessment Group (BILAG) A and no more than 1 new BILAG B domain score and 3)no worsening in Physician Global Assessment (PGA) of Disease Activity (worsening defined as an increase of \>=0.3 from baseline on a 0-3 visual analogue scale). SLEDAI-2K assessment consists of 24 items with total score of 0(no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms,or laboratory parameters related to Systemic Lupus Erythematosus (SLE),divided into 9 organ systems. For each organ system A=severe disease,B=moderate disease,C=mild stable disease,D=inactive,but previously active,E=inactive and never affected. PGA assesses disease activity on a visual analogue scale from 0 to 3 (1=mild, 2=moderate, 3=severe).

    Time frame: Week 134

  2. Percentage of Participants Achieving a Lupus Low Disease Activity State (LLDAS)

    Percentage of participants achieving a LLDAS. The LLDAS is a composite measure designed to identify patients achieving a state of low disease activity. The LLDAS response criteria were: (1) SLEDAI-2K \<=4, with no activity in major organ systems (CNS, vascular, renal, cardiorespiratory and constitutional); where "no activity" is defined as all items of SLEDAI-2K within these major organ systems equal to 0. (2) no new features of lupus disease activity compared to previous occurred visit, where the "new feature" is defined as any of the SLEDAI-2K 24 items changed from 0 to greater than 0; (3) PGA (scale 0-3), \<=1; (4) current prednisolone (or equivalent) dose \<=7.5 mg daily.

    Time frame: Week 48

  3. Change From Baseline in Prednisone Dose

    Change from baseline in prednisone dose.

    Time frame: Baseline through Week 48

  4. Annualized Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA)-Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) Flare Index Flare Rate

    The SELENA-SLEDAI tool is a cumulative and weighted index used to assess disease activity across 24 different disease descriptors in patients with lupus. A patient's SELENA-SLEDAI total score is the sum of all marked lupus related descriptors (seizure, psychosis, organic brain syndrome, visual disturbance, cranial nerve disorder, lupus headache, cerebrovascular accident, vasculitis, arthritis, myositis, urinary casts, hematuria, proteinuria, pyuria, new rash, alopecia, mucosal ulcers, pleurisy, pericarditis, low complement, increased DNA binding, fever, thrombocytopenia, leukopenia). A total score can fall between 0 and 105, with a higher score representing a more significant degree of disease activity. The annualized flare rate is calculated as the number of flares divided by the flare exposure time in days multiplied with 365.25.

    Time frame: Baseline through Week 48

  5. Percentage of Participants With Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Total Activity Score ≥10 at Baseline With ≥50% Reduction in CLASI Total Activity Score

    The CLASI is a single-page tool that separately quantifies disease activity and damage. For the activity score, points are given for the presence of erythema, scale, mucous membrane lesions, recent hair loss, and inflammatory alopecia. The total score represents the sum of the individual scores and ranges from 0 to 70. Higher scores are awarded for more severe manifestations.

    Time frame: Week 48

  6. Change From Baseline in Tender Joint Count

    The number of tender and painful joints is determined by examination of 28 joints (14 on each side) which include: the 2 shoulders, the 2 elbows, the 2 wrists, the 10 metacarpophalangeal joints, the 2 interphalangeal joints of the thumb, the 8 proximal interphalangeal joints, and the 2 knees. The joints are assessed and classified as tender or not tender. LS mean was calculated using Mixed Model Repeated Measures (MMRM) analysis with treatment, baseline disease activity (total SLEDAI-2K \<10; \>=10), baseline corticosteroid dose (\<10 mg/day; \>=10 mg/day prednisone or equivalent), region (North America, Central/South America/Mexico, Europe, Asia and Rest of World), visit (as categorical variable), baseline value, treatment-by-visit interaction, and baseline value-by-visit interaction.

    Time frame: Baseline through Week 48

  7. Change From Baseline in Swollen Joint Count

    The number of swollen joints is determined by examination of 28 joints (14 on each side) which include: the 2 shoulders, the 2 elbows, the 2 wrists, the 10 metacarpophalangeal joints, the 2 interphalangeal joints of the thumb, the 8 proximal interphalangeal joints, and the 2 knees. The joints are assessed and classified as swollen or not swollen. LS mean was calculated using MMRM analysis with treatment, baseline disease activity (total SLEDAI-2K \<10; \>=10), baseline corticosteroid dose (\<10 mg/day; \>=10 mg/day prednisone or equivalent), region (North America, Central/South America/Mexico, Europe, Asia and Rest of World), visit (as categorical variable), baseline value, treatment-by-visit interaction, and baseline value-by-visit interaction.

    Time frame: Baseline trough Week 48

  8. Change From Baseline in Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index Total Score

    The SLICC/ACR damage index is a validated instrument to assess damage, defined as irreversible impairment, continuously persistent for 6 months (ascertained by clinical assessment), occurring since the onset of lupus, and it is based on a weighted scoring system. This index records damage occurring in participants with SLE regardless of cause, with demonstrated content, face, criterion, and discriminant validity. A score of 0 indicates no damage. Total maximum score is 47 and increasing score indicates increasing disease severity.

    Time frame: Baseline through Week 48

  9. Change From Baseline in Worst Pain Numeric Rating Scale (NRS)

    Change from baseline in Worst Pain NRS. It is assessed using an 11-point Numeric Rating Scale (NRS) (0-10) where 0 represents "no pain" and 10 represents "worst pain imaginable". Overall severity of a patient's pain is indicated by selecting the number that best describes the worst level of pain during the past 7 days.

    Time frame: Baseline through Week 48

07

Results

Posted May 16, 2023
Limitations and caveats
This study was terminated due to insufficient evidence to support a positive benefit: risk profile. Safety findings were consistent with previously published OLUMIANT data.

Participant flow

Participants who completed originating study \[I4V-MC-JAHZ (NCT03616912) or Study I4V-MC-JAIA (NCT03616964)\] were enrolled in this study.

Participant flow — Overall Study
Milestone2 Milligrams (mg) Baricitinib4 mg BaricitinibPlacebo to 2 mg BaricitinibPlacebo to 4 mg Baricitinib
Started388379189191
Safety population388378189191
Completed0000
Not completed388379189191
Withdrew: Adverse event171359
Withdrew: Death0620
Withdrew: Lack of efficacy141194
Withdrew: Lost to follow-up3402
Withdrew: Other121434
Withdrew: Due to epidemic/pandemic1000
Withdrew: Study terminated by sponsor318318163163
Withdrew: Withdrawal by subject231269
Withdrew: Missing data0110

Outcome measures

PrimaryPercentage of Participants With Treatment-Emergent Adverse Events (TEAEs)

Percentage of participants with TEAEs. A treatment-emergent AE (TEAE) is defined as an event that first occurred or worsened in severity after the first dose of study treatment in Study JAIM and on or prior to the last visit date during the analysis period. The analysis period is defined as the treatment period plus up to 30 days off-drug follow-up time. A summary of serious and other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events module.

Time frame:
Week 134
Reported as:
Number · Percentage of Participants
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)
Percentage of Participants2 mg Baricitinib4 mg BaricitinibPlacebo to 2 mg BaricitinibPlacebo to 4 mg Baricitinib
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)61.968.865.164.4
PrimaryPercentage of Participants With Adverse Events of Special Interest (AESIs)

Percentage of Participants with AESIs. AESI consisted of infections, positively adjudicated arterial thromboembolic events (ATE), positively adjudicated venous thromboembolic events (VTE), positively adjudicated major adverse cardiovascular events (MACE), other positively adjudicated cardiovascular events, death, anaphylactic reactions, hypersensitivity, angioedema, and malignancies.

Time frame:
Week 134
Reported as:
Number · Percentage of participants
Percentage of Participants With Adverse Events of Special Interest (AESIs)
Percentage of participants2 mg Baricitinib4 mg BaricitinibPlacebo to 2 mg BaricitinibPlacebo to 4 mg Baricitinib
Infections38.442.136.535.1
Positively adjudicated ATE0.30.80.50.5
Positively adjudicated VTE0.31.10.50.5
Positively adjudicated MACE0.30.80.50.5
Other positively adjudicated cardiovascular events0.30.800.5
Death01.61.10
Anaphylactic reactions3.64.25.83.1
Hypersensitivity3.64.25.83.1
Angioedema1.30.81.60
Malignancies0.50.300
PrimaryPercentage of Participants With Serious Adverse Events (SAEs)

Percentage of participants with SAEs. An SAE is any AE from this study that results in one of the following outcomes: Death; Initial or prolonged inpatient hospitalization; A life-threatening experience (that is, immediate risk of dying); Persistent or significant disability/incapacity; Congenital anomaly/birth defect; Important medical events that may not be immediately life-threatening or result in death or hospitalization, but may jeopardize the patient or may require intervention to prevent one of the other outcomes listed in the definition above. A summary of all SAE's, regardless of causality, is located in the Reported Adverse Events section.

Time frame:
Week 134
Reported as:
Number · Percentage of Participants
Percentage of Participants With Serious Adverse Events (SAEs)
Percentage of Participants2 mg Baricitinib4 mg BaricitinibPlacebo to 2 mg BaricitinibPlacebo to 4 mg Baricitinib
Percentage of Participants With Serious Adverse Events (SAEs)11.113.511.111.5
PrimaryPercentage of Participants With Temporary Investigational Product Interruptions

Percentage of participants with temporary investigational product interruptions.

Time frame:
Week 134
Reported as:
Number · Percentage of Participants
Percentage of Participants With Temporary Investigational Product Interruptions
Percentage of Participants2 mg Baricitinib4 mg BaricitinibPlacebo to 2 mg BaricitinibPlacebo to 4 mg Baricitinib
Percentage of Participants With Temporary Investigational Product Interruptions19.124.618.523.6
PrimaryPercentage of Participants With Permanent Investigational Product Discontinuations

Percentage of participants with permanent investigational product discontinuations.

Time frame:
Week 134
Reported as:
Number · Percentage of Participants
Percentage of Participants With Permanent Investigational Product Discontinuations
Percentage of Participants2 mg Baricitinib4 mg BaricitinibPlacebo to 2 mg BaricitinibPlacebo to 4 mg Baricitinib
Percentage of Participants With Permanent Investigational Product Discontinuations5.25.84.25.8
SecondaryPercentage of Participants Achieving a Systemic Lupus Erythematosus Responder Index 4 (SRI-4) Response

SRI-4 response defined as 1)greater than or equal to 4-point reduction in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) total score 2)no new British Isles Lupus Assessment Group (BILAG) A and no more than 1 new BILAG B domain score and 3)no worsening in Physician Global Assessment (PGA) of Disease Activity (worsening defined as an increase of \>=0.3 from baseline on a 0-3 visual analogue scale). SLEDAI-2K assessment consists of 24 items with total score of 0(no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms,or laboratory parameters related to Systemic Lupus Erythematosus (SLE),divided into 9 organ systems. For each organ system A=severe disease,B=moderate disease,C=mild stable disease,D=inactive,but previously active,E=inactive and never affected. PGA assesses disease activity on a visual analogue scale from 0 to 3 (1=mild, 2=moderate, 3=severe).

Time frame:
Week 134
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving a Systemic Lupus Erythematosus Responder Index 4 (SRI-4) Response
Percentage of participants2 mg Baricitinib4 mg BaricitinibPlacebo to 2 mg BaricitinibPlacebo to 4 mg Baricitinib
Percentage of Participants Achieving a Systemic Lupus Erythematosus Responder Index 4 (SRI-4) Response0000
SecondaryPercentage of Participants Achieving a Lupus Low Disease Activity State (LLDAS)

Percentage of participants achieving a LLDAS. The LLDAS is a composite measure designed to identify patients achieving a state of low disease activity. The LLDAS response criteria were: (1) SLEDAI-2K \<=4, with no activity in major organ systems (CNS, vascular, renal, cardiorespiratory and constitutional); where "no activity" is defined as all items of SLEDAI-2K within these major organ systems equal to 0. (2) no new features of lupus disease activity compared to previous occurred visit, where the "new feature" is defined as any of the SLEDAI-2K 24 items changed from 0 to greater than 0; (3) PGA (scale 0-3), \<=1; (4) current prednisolone (or equivalent) dose \<=7.5 mg daily.

Time frame:
Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving a Lupus Low Disease Activity State (LLDAS)
Percentage of participants2 mg Baricitinib4 mg BaricitinibPlacebo to 2 mg BaricitinibPlacebo to 4 mg Baricitinib
Percentage of Participants Achieving a Lupus Low Disease Activity State (LLDAS)29.833.019.426.0
SecondaryChange From Baseline in Prednisone Dose

Change from baseline in prednisone dose.

Time frame:
Baseline through Week 48
Reported as:
Least squares mean · milligrams (mg)
Change From Baseline in Prednisone Dose
milligrams (mg)2 mg Baricitinib4 mg BaricitinibPlacebo to 2 mg BaricitinibPlacebo to 4 mg Baricitinib
Change From Baseline in Prednisone Dose2.35 ± 0.3052.27 ± 0.3161.68 ± 0.4261.00 ± 0.419
SecondaryAnnualized Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA)-Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) Flare Index Flare Rate

The SELENA-SLEDAI tool is a cumulative and weighted index used to assess disease activity across 24 different disease descriptors in patients with lupus. A patient's SELENA-SLEDAI total score is the sum of all marked lupus related descriptors (seizure, psychosis, organic brain syndrome, visual disturbance, cranial nerve disorder, lupus headache, cerebrovascular accident, vasculitis, arthritis, myositis, urinary casts, hematuria, proteinuria, pyuria, new rash, alopecia, mucosal ulcers, pleurisy, pericarditis, low complement, increased DNA binding, fever, thrombocytopenia, leukopenia). A total score can fall between 0 and 105, with a higher score representing a more significant degree of disease activity. The annualized flare rate is calculated as the number of flares divided by the flare exposure time in days multiplied with 365.25.

Time frame:
Baseline through Week 48
Reported as:
Number · flares per year
Annualized Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA)-Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) Flare Index Flare Rate
flares per year2 mg Baricitinib4 mg BaricitinibPlacebo to 2 mg BaricitinibPlacebo to 4 mg Baricitinib
Annualized Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA)-Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) Flare Index Flare Rate0.9780.9260.8940.746
SecondaryPercentage of Participants With Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Total Activity Score ≥10 at Baseline With ≥50% Reduction in CLASI Total Activity Score

The CLASI is a single-page tool that separately quantifies disease activity and damage. For the activity score, points are given for the presence of erythema, scale, mucous membrane lesions, recent hair loss, and inflammatory alopecia. The total score represents the sum of the individual scores and ranges from 0 to 70. Higher scores are awarded for more severe manifestations.

Time frame:
Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants With Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Total Activity Score ≥10 at Baseline With ≥50% Reduction in CLASI Total Activity Score
Percentage of participants2 mg Baricitinib4 mg BaricitinibPlacebo to 2 mg BaricitinibPlacebo to 4 mg Baricitinib
Percentage of Participants With Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Total Activity Score ≥10 at Baseline With ≥50% Reduction in CLASI Total Activity Score55.964.060.020.0
SecondaryChange From Baseline in Tender Joint Count

The number of tender and painful joints is determined by examination of 28 joints (14 on each side) which include: the 2 shoulders, the 2 elbows, the 2 wrists, the 10 metacarpophalangeal joints, the 2 interphalangeal joints of the thumb, the 8 proximal interphalangeal joints, and the 2 knees. The joints are assessed and classified as tender or not tender. LS mean was calculated using Mixed Model Repeated Measures (MMRM) analysis with treatment, baseline disease activity (total SLEDAI-2K \<10; \>=10), baseline corticosteroid dose (\<10 mg/day; \>=10 mg/day prednisone or equivalent), region (North America, Central/South America/Mexico, Europe, Asia and Rest of World), visit (as categorical variable), baseline value, treatment-by-visit interaction, and baseline value-by-visit interaction.

Time frame:
Baseline through Week 48
Reported as:
Least squares mean · tender joints
Change From Baseline in Tender Joint Count
tender joints2 mg Baricitinib4 mg BaricitinibPlacebo to 2 mg BaricitinibPlacebo to 4 mg Baricitinib
Change From Baseline in Tender Joint Count-5.68 ± 0.281-5.85 ± 0.292-3.62 ± 0.383-3.73 ± 0.376
SecondaryChange From Baseline in Swollen Joint Count

The number of swollen joints is determined by examination of 28 joints (14 on each side) which include: the 2 shoulders, the 2 elbows, the 2 wrists, the 10 metacarpophalangeal joints, the 2 interphalangeal joints of the thumb, the 8 proximal interphalangeal joints, and the 2 knees. The joints are assessed and classified as swollen or not swollen. LS mean was calculated using MMRM analysis with treatment, baseline disease activity (total SLEDAI-2K \<10; \>=10), baseline corticosteroid dose (\<10 mg/day; \>=10 mg/day prednisone or equivalent), region (North America, Central/South America/Mexico, Europe, Asia and Rest of World), visit (as categorical variable), baseline value, treatment-by-visit interaction, and baseline value-by-visit interaction.

Time frame:
Baseline trough Week 48
Reported as:
Least squares mean · swollen joints
Change From Baseline in Swollen Joint Count
swollen joints2 mg Baricitinib4 mg BaricitinibPlacebo to 2 mg BaricitinibPlacebo to 4 mg Baricitinib
Change From Baseline in Swollen Joint Count-4.03 ± 0.191-4.01 ± 0.196-3.19 ± 0.264-2.94 ± 0.257
SecondaryChange From Baseline in Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index Total Score

The SLICC/ACR damage index is a validated instrument to assess damage, defined as irreversible impairment, continuously persistent for 6 months (ascertained by clinical assessment), occurring since the onset of lupus, and it is based on a weighted scoring system. This index records damage occurring in participants with SLE regardless of cause, with demonstrated content, face, criterion, and discriminant validity. A score of 0 indicates no damage. Total maximum score is 47 and increasing score indicates increasing disease severity.

Time frame:
Baseline through Week 48
Reported as:
Mean · Score on a scale
Change From Baseline in Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index Total Score
Score on a scale2 mg Baricitinib4 mg BaricitinibPlacebo to 2 mg BaricitinibPlacebo to 4 mg Baricitinib
Change From Baseline in Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index Total Score-0.03 ± 0.569-0.04 ± 0.544-0.04 ± 0.754-0.06 ± 0.505
SecondaryChange From Baseline in Worst Pain Numeric Rating Scale (NRS)

Change from baseline in Worst Pain NRS. It is assessed using an 11-point Numeric Rating Scale (NRS) (0-10) where 0 represents "no pain" and 10 represents "worst pain imaginable". Overall severity of a patient's pain is indicated by selecting the number that best describes the worst level of pain during the past 7 days.

Time frame:
Baseline through Week 48
Reported as:
Least squares mean · Score on a scale
Change From Baseline in Worst Pain Numeric Rating Scale (NRS)
Score on a scale2 mg Baricitinib4 mg BaricitinibPlacebo to 2 mg BaricitinibPlacebo to 4 mg Baricitinib
Change From Baseline in Worst Pain Numeric Rating Scale (NRS)-0.96 ± 0.167-1.23 ± 0.173-0.55 ± 0.222-0.83 ± 0.218

Adverse events

Collected over Baseline through Study Completion (Up to 134 Weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
2 mg Baricitinib0/388 (0%)43/388 (11.1%)54/388 (13.9%)
4 mg Baricitinib6/378 (1.6%)53/378 (14%)54/378 (14.3%)
Placebo to 2 mg Baricitinib2/189 (1.1%)21/189 (11.1%)35/189 (18.5%)
Placebo to 4 mg Baricitinib0/191 (0%)22/191 (11.5%)29/191 (15.2%)
Most frequent serious events
Showing 10 of 137
Most frequent serious events
Event2 mg Baricitinib4 mg BaricitinibPlacebo to 2 mg BaricitinibPlacebo to 4 mg Baricitinib
Covid-19Infections and infestations0/3887/3783/1890/191
OsteonecrosisMusculoskeletal and connective tissue disorders1/3880/3783/1890/191
Covid-19 pneumoniaInfections and infestations5/3885/3780/1893/191
Escherichia pyelonephritisInfections and infestations0/3880/3780/1893/191
Systemic lupus erythematosusMusculoskeletal and connective tissue disorders2/3885/3781/1893/191
CholelithiasisHepatobiliary disorders0/3880/3780/1892/191
Urinary tract infectionInfections and infestations0/3882/3781/1892/191
ArthritisMusculoskeletal and connective tissue disorders0/3880/3780/1892/191
PneumoniaInfections and infestations4/3881/3781/1890/191
Cervical dysplasiaReproductive system and breast disorders2/3611/3560/1810/176
Most frequent other events
Most frequent other events
Event2 mg Baricitinib4 mg BaricitinibPlacebo to 2 mg BaricitinibPlacebo to 4 mg Baricitinib
Covid-19Infections and infestations35/38832/37821/18923/191
Urinary tract infectionInfections and infestations20/38822/37817/1897/191

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)2 mg Baricitinib4 mg BaricitinibPlacebo to 2 mg BaricitinibPlacebo to 4 mg BaricitinibTotal
Mean43.8 ± 12.6843.8 ± 12.0343.8 ± 11.8543.5 ± 13.2243.7 ± 12.41
Sex: Female, Male
Sex: Female, Male(Participants)2 mg Baricitinib4 mg BaricitinibPlacebo to 2 mg BaricitinibPlacebo to 4 mg BaricitinibTotal
Female3613571811761075
Male272281572
Race (NIH/OMB)
Race (NIH/OMB)(Participants)2 mg Baricitinib4 mg BaricitinibPlacebo to 2 mg BaricitinibPlacebo to 4 mg BaricitinibTotal
American Indian or Alaska Native2116131161
Asian79774441241
Native Hawaiian or Other Pacific Islander00000
Black or African American32361919106
White249241109115714
More than one race32229
Unknown or Not Reported472316
Region of Enrollment
Region of Enrollment(Participants)2 mg Baricitinib4 mg BaricitinibPlacebo to 2 mg BaricitinibPlacebo to 4 mg BaricitinibTotal
United States66682830192
Czechia797528
Russia1916111157
Greece840315
South Korea772218
Netherlands11002
Austria11002
China171810651
Poland2728111379
Brazil1719141060
France01012
Serbia18153743
Chile1274427
Croatia31116
Colombia11138739
Argentina2123131673
Romania1163424
Hungary16135539
Japan694524
Philippines1385733
United Kingdom333110
Switzerland00202
India2020131265
Spain396321
Belgium11103
Taiwan8105730
Italy20114
Mexico40401517112
South Africa1396634
Israel33006
Australia564217
Germany9114529
08

Study locations

297 sites
  • Achieve Clinical Research, LLC
    Birmingham, Alabama 35216, United States
  • Arizona Arthritis & Rheumatology Research
    Phoenix, Arizona 85032, United States
  • Arizona Arthritis & Rheumatology Associates, P. C.
    Tucson, Arizona 85704, United States
  • Wallace Rheumatic Studies Center
    Beverly Hills, California 90211, United States
  • Medvin Clinical Research - Weidmann
    Covina, California 91722, United States
  • Providence Medical Foundation
    Fullerton, California 92835, United States
  • MD Medical Corporation
    Hemet, California 92543, United States
  • ACRC Studies
    Poway, California 92064, United States
  • Inland Rheumatology & Osteoporosis Medical Group
    Upland, California 91786, United States
  • Medvin Clinical Research - Weidmann
    Whittier, California 90602, United States
  • Denver Arthritis Clinic - Lowry
    Denver, Colorado 80230, United States
  • New England Research Associates
    Bridgeport, Connecticut 06606, United States
  • Arthritis and Rheumatic Disease
    Aventura, Florida 33180, United States
  • Clinical Research of West Florida, Inc. (Clearwater)
    Clearwater, Florida 33765, United States
  • Lakes Research, LLC
    Miami Lakes, Florida 33014, United States
  • Millennium Research
    Ormond Beach, Florida 32174, United States
  • Integral Rheumatology & Immunology Specialists
    Plantation, Florida 33324, United States
  • IRIS Research and Development, LLC
    Plantation, Florida 33324, United States
  • ForCare Clinical Research
    Tampa, Florida 33613-1244, United States
  • Tampa Medical Group, P.A.
    Tampa, Florida 33614, United States
  • Piedmont Healthcare
    Atlanta, Georgia 30318, United States
  • Emory University
    Atlanta, Georgia 30322, United States
  • North Georgia Rheumatology, PC
    Lawrenceville, Georgia 30046, United States
  • Arthritis Center of Lexington
    Lexington, Kentucky 40504, United States
  • Johns Hopkins Asthma and Allergy Center
    Baltimore, Maryland 21224, United States
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
  • Advanced Rheumatology, PC
    Lansing, Michigan 48910, United States
  • Clinical Research Institute of Michigan, LLC
    Saint Clair Shores, Michigan 48081, United States
  • Glacir View Research Institute
    Kalispell, Montana 59901, United States
  • Allied Clinical Research
    Reno, Nevada 89519, United States
  • Arthritis and Osteoporosis Associates of New Mexico
    Las Cruces, New Mexico 88011, United States
  • St. Lawrence Health System
    Canton, New York 13617, United States
  • The Feinstein Institute for Medical Research
    Manhasset, New York 11030, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • NYU Langone
    New York, New York 11201, United States
  • SUNY Upstate Medical University
    Syracuse, New York 13210, United States
  • Joint and Muscle Medical Care
    Charlotte, North Carolina 28204, United States
  • Box Arthritis & Rheumatology of the Carolinas, PLLC
    Charlotte, North Carolina 28210, United States
  • Medication Management
    Greensboro, North Carolina 27408, United States
  • Cincinnati Rheumatic Disease Study Group
    Cincinnati, Ohio 45242, United States
  • Paramount Medical Research
    Middleburg Heights, Ohio 44130, United States
  • Arthritis & Rheumatology Center of Oklahoma PLLC
    Oklahoma City, Oklahoma 73102, United States
  • Oklahoma Medical Research Foundation
    Oklahoma City, Oklahoma 73104-5046, United States
  • East Penn Rheumatology Associates
    Bethlehem, Pennsylvania 18015, United States
  • Clinical Research Center of Reading,LLC
    Wyomissing, Pennsylvania 19610, United States
  • Articularis Healthcare d/b/a/ Low Country Rheumatology, PA
    Summerville, South Carolina 29486, United States
  • Eagle Medical
    Crossville, Tennessee 38555, United States
  • West Tennessee Research Institute
    Jackson, Tennessee 38305, United States
  • Amarillo Center for Clinical Research
    Amarillo, Texas 79124, United States
  • Accurate Clinical Management
    Baytown, Texas 77521, United States
  • Dr. Dhiman Basu Private Practice
    Colleyville, Texas 76034, United States
  • Metroplex Clinical Research Center
    Dallas, Texas 75231, United States
  • Precision Comprehensive Clinical Research Solutions
    Fort Worth, Texas 76107, United States
  • Rheumatology Center Of Houston
    Houston, Texas 77004, United States
  • Accurate Clinical Research
    Houston, Texas 77089, United States
  • Southwest Rheumatology, P.A.
    Mesquite, Texas 75150, United States
  • Accurate Clinical Research, Inc.
    San Antonio, Texas 78229, United States
  • Advanced Rheumatology of Houston
    The Woodlands, Texas 77382, United States
  • Arthritis Clinic of Northern VA, P.C.
    Arlington, Virginia 22205, United States
  • Spectrum Medical Inc.
    Danville, Virginia 24541, United States
  • Rheumatic Disease Center
    Glendale, Wisconsin 53217, United States
  • Aprillus Asistencia e Investigacion de Arcis Salud SRL
    Ciudad Autónoma de Buenos Aire, Buenos Aires 1046, Argentina
  • DOM Centro de Reumatologia
    Ciudad de Buenos Aires, Buenos Aires C1111AAH, Argentina
  • Framingham Centro Medico
    La Plata, Buenos Aires B1902COS, Argentina
  • CER Instituto Medico
    Quilmes, Buenos Aires B1878DVC, Argentina
  • Instituto de Investigaciones Clinicas Quilmes
    Quilmes, Buenos Aires B1878GEG, Argentina
  • Clinica Adventista Belgrano
    Caba, Ciudad Autónoma De Buenos Aire C1430EGF, Argentina
  • Sanatorio Británico
    Rosario, Santa Fe 2000, Argentina
  • Centro de Educación Médica e Investigaciones Clínicas "Norberto Quirno" (CEMIC)
    Buenos Aires, C1431FWO, Argentina
  • IR Medical Center S.A. Instituto de Reumatologia
    Mendoza, M5500CPH, Argentina
  • Centro de Investigaciones Médicas Tucuman
    Tucumán, T4000AXL, Argentina
  • Optimus Clinical Research
    Botany, New South Wales 2019, Australia
  • The Rheumatology Research Unit Sunshine Coast
    Maroochydore, Queensland 4558, Australia
  • Emeritus Research
    Camberwell, Victoria 3124, Australia
  • St. Vincent's Hospital
    Fitzroy, Victoria 3065, Australia
  • A O Krankenhaus der Elisabethinen
    Linz, Oberösterreich 4020, Austria
  • Medizinische Universität Graz
    Graz, 8036, Austria
  • UZ Leuven
    Leuven, Vlaams Brabant 3000, Belgium
  • Cliniques Universitaires Saint-Luc
    Brussels, 1200, Belgium
  • SER - Serviços Especializados em Reumatologia da Bahia S/S - ME
    Salvador, Bahia 40150-150, Brazil
  • Santa Casa de Misericordia de Belo Horizonte
    Belo Horizonte, MG 30150-221, Brazil
  • Centro de Estudos em Terapias Inovadoras-CETI
    Curitiba, Paraná 80030-110, Brazil
  • EDUMED - Educação em Saúde Ltda.
    Curitiba, Paraná 80440-080, Brazil
  • LMK Serviços Médicos S/S
    Porto Alegre, Rio Grande Do Sul 90540-000, Brazil
  • Hospital de Clinicas UNICAMP
    Campinas, SP 13083-970, Brazil
  • Oncovida- Centro de Onco-Hematologia de Mato Grosso
    Cuiaba, 78043-142, Brazil
  • Clinical Research Chile SpA
    Valdivia, Los Ríos 5110683, Chile
  • Enroll SpA
    Providencia, Región Metropolitana De Santia 7500587, Chile
  • Clinica Alemana de Osorno
    Osorno, 5290000, Chile
  • Sociedad Medica Del Aparato Locomotor SA
    Santiago, 7510186, Chile
  • Prosalud y cia. Ltda.
    Santiago, Chile
  • CINVEC- Estudos Clínicos Quinta Región Limitada
    Vina del Mar, 2570017, Chile
  • First affiliated Hospital of Sun Yat-Sen University
    Guangzhou, Guangdong 510080, China
  • First Affiliated Hospital of the Harbin Medical University
    Harbin, Heilongjiang 150001, China
  • Wuhan Union Hospital
    Wuhan, Hubei 430022, China
  • Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School
    Nanjing, Jiangsu 210000, China
  • Pingxiang People's Hospital
    Pingxiang, Jiangxi 337000, China
  • China-Japan Union Hospital, CJUH.
    Changchun, Jilin 130033, China
  • Zhongshan Hospital, Fudan University
    Shanghai, Shanghai 200032, China
  • Tianjin Medical University General Hospital
    Tianjin, Tianjin 300052, China

Showing the first 100 of 297 sites across 32 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2019 to primary completion in Apr 2022, 30 months.

Results were first posted in May 2023, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2019
First posted
Feb 15, 2019
StartActual
Sep 9, 2019
Primary completionActual
Apr 1, 2022
CompletionActual
Apr 1, 2022
Results first posted
May 16, 2023
Last update
May 16, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03843125
Collaborators
Incyte Corporation
Responsible party
Sponsor
First posted
Feb 15, 2019
Start date
Sep 9, 2019
Primary completion
Apr 1, 2022
Completion
Apr 1, 2022
Results posted
May 16, 2023
Last update
May 16, 2023

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Baricitinib

Start the discussion